Track Biocon Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.
1 Week returns: -2.61 %
Low
342.1
High
361.1
1 Month returns: -10.25 %
Low
342.1
High
399.0
1 Year returns: -0.34 %
Low
337.7
High
447.1
3 Year CAGR: 11.28 %
Low
217.5
High
447.1
5 Year CAGR: 0.17 %
Low
191.6
High
447.1
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
Multi-year trends for Biocon Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Biocon Ltd. Shareholding Pattern
Quarterly breakdown of Biocon Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Biocon Ltd. shares as reported to NSE and BSE.
Frequently Asked Questions
What is the current share price of Biocon Ltd.?
The current share price of Biocon Ltd. is ₹ 350.60 as of 14 Oct 2026.
What is the market capitalisation of Biocon Ltd.?
The market capitalisation of Biocon Ltd. stands at ₹ 57,106.70 Cr.
What is the PE ratio of Biocon Ltd.?
The Price-to-Earnings (PE) ratio of Biocon Ltd. is 115.30 as of the latest trailing twelve months data.
What is the ROE and ROCE of Biocon Ltd.?
Biocon Ltd. has a Return on Equity (ROE) of 1.39% and a Return on Capital Employed (ROCE) of 3.45% as per the latest financial reports.
What is the 52-week high and low of Biocon Ltd.?
The 52-week high of Biocon Ltd. is - and the 52-week low is -.
What is the dividend yield of Biocon Ltd.?
The dividend yield of Biocon Ltd. is 0.14% based on the current market price.
What is the FII and DII holding in Biocon Ltd.?
Foreign Institutional Investors (FII) hold 8.14%, Domestic Institutional Investors (DII) hold 21.95% and retail/public investors hold 17.65% of Biocon Ltd. shares.
What sector does Biocon Ltd. belong to?
Biocon Ltd. operates in the Healthcare sector. 43.75% of analysts have a Buy or Strong Buy rating on Biocon Ltd. with a consensus target price of ₹ 432.50, implying 23.36% upside from current levels.
What is the beta of Biocon Ltd.?
The beta of Biocon Ltd. is 0.66, indicating its price volatility relative to the broader market. Over the past 1 year, Biocon Ltd. has delivered an absolute return of 0.77%.
What is the RSI of Biocon Ltd.?
The 14-day Relative Strength Index (RSI) of Biocon Ltd. is 27.94, placing it in the oversold zone. An RSI above 70 is considered overbought and below 30 is considered oversold.
Stock Analysis
Fundamental analysis overview of Biocon Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Views
Red Flags
Positive
Low and declining Debt to Equity
The company has low Debt to Equity of 0.45 as on 30 Jun 2026 and Debt to Equity decreased by 0.4 in the last 1 year
What is Debt to Equity?
Consistently pays dividend
The company has not missed dividend payments once in the last 4 financial years
What is Dividend streak?
Negative
Expensive and at a premium to industry median P/E
PE TTM of 115.3 indicates that the stock is expensive on a standalone basis and is at a 264.76% premium to industry median P/E
What is P/E Ratio?
Median: 31.61
Value 115.3
-0.8705.79
Analysts have been downgrading forward EPS estimates
Analyst EPS estimate (consensus) for forward EPS has decreased by -8.32% in the last 3 months, indicating weak earnings momentum
What is Earnings upgrade (3M)?
Low and declining ROE
The company reported low ROE of 1.39% for 12-month ended 30 Jun 2026 and ROE declined by -350 bps from 1 year ago
What is ROE (FY)?
Low but stable operating margin
The company reported low operating margin of 8.59% for 12-month ended 30 Jun 2026 and operating margin declined marginally by -110 bps from 1 year ago
What is Operating profit margin?
Low revenue growth and in line with median growth of industry
The company delivered low revenue growth of 9.83% for 12-month ended 30 Jun 2026 and the growth was 0.85 percentage points lower than median growth of industry
What is Sales growth (1Y)?
Median: 10.68
Value 9.83
-99.6111701.8
Low EPS growth and lower than median growth of industry
The company delivered moderate EPS growth of 5.23% for 12-month ended 30 Jun 2026 and the growth was 2.22 percentage points lower than median growth of industry
What is EPS growth (1Y)?
Low dividend yield
The company has a low dividend yield of 0.14%
What is Dividend yield?
Neutral
Company's earnings are of moderate quality
Earnings quality score of 68.8 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion
What is Earnings quality score?
68.8 / 100
No red flags found!
No significant red flags found in the stock.
Net Revenue FY
Profit After Tax FY
ROE FY
EBITDA FY
Mar 2020
Jun 2020
Sep 2020
Dec 2020
Mar 2021
Jun 2021
Sep 2021
Dec 2021
Mar 2022
Jun 2022
Sep 2022
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Promoter
60.67
60.67
60.67
60.67
60.67
60.64
60.64
60.64
60.64
60.64
60.64
60.64
60.64
60.64
60.64
60.64
60.64
60.64
60.64
60.64
60.64
54.45
54.45
54.45
44.91
44.68
Indian Promoter
39.75
39.75
39.75
39.75
39.75
39.73
39.73
39.73
39.73
39.73
39.66
39.66
39.66
39.66
40.36
40.36
40.36
40.36
40.36
40.36
40.36
36.24
36.24
36.24
29.90
29.73
Foreign Promoter
20.92
20.92
20.92
20.92
20.92
20.91
20.91
20.91
20.91
20.91
20.98
20.98
20.98
20.98
20.28
20.28
20.28
20.28
20.28
20.28
20.28
18.21
18.21
18.21
15.02
14.94
Institutions
22.30
23.11
22.98
23.68
23.44
23.43
23.18
23.37
23.98
24.03
23.55
23.05
22.10
22.11
22.05
21.06
19.31
20.20
20.37
21.02
21.38
28.86
28.71
29.10
31.59
31.52
Mutual Funds / UTI
5.13
4.69
3.94
3.05
2.51
2.60
2.58
2.54
3.52
3.05
3.21
3.95
7.19
7.47
8.26
9.31
8.57
8.69
7.97
8.58
8.77
15.24
14.13
13.75
16.53
15.47
FI/Bank/Insurance
1.62
1.77
1.68
2.30
4.13
4.30
4.29
4.29
4.27
4.25
4.55
4.69
4.68
5.09
5.76
5.12
5.02
5.53
6.25
6.43
6.55
6.79
7.12
6.91
6.24
6.48
Govt
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
FII
14.98
15.93
16.69
17.65
16.30
15.91
15.74
16.00
15.62
16.31
15.79
14.42
10.20
9.52
7.97
6.55
5.63
5.90
5.93
5.66
5.67
6.04
6.61
7.39
7.52
8.14
Other Institutions
0.57
1.45
0.68
0.68
0.49
0.64
1.13
0.54
1.12
0.84
0.00
0.00
0.02
0.03
0.06
0.08
0.10
0.07
0.22
0.35
0.41
0.80
0.84
1.04
1.29
1.43
Non-Institution
17.03
16.21
16.35
15.65
15.89
15.93
16.18
15.99
15.39
15.33
15.81
16.31
17.27
17.26
17.32
18.30
20.05
19.17
18.99
18.34
17.97
16.68
16.83
16.45
23.49
23.80
Bodies Corporate
1.19
1.03
1.02
0.91
0.99
1.00
1.02
1.03
1.02
1.02
0.97
1.00
0.97
0.91
0.90
1.04
1.46
1.50
1.47
1.38
1.46
1.48
1.63
1.64
6.17
6.15
Others (incl. Retail)
No. of shareholders
15.84
2,05,742
15.18
2,27,718
15.33
2,47,348
14.74
2,62,932
14.90
3,09,856
14.93
3,37,275
15.16
3,61,824
14.96
3,62,927
14.37
3,46,413
14.31
3,39,551
14.84
3,68,332
15.31
3,89,857
16.30
4,09,674
16.35
4,11,019
16.42
4,13,594
17.26
4,32,846
18.59
4,68,611
17.67
4,41,741
17.52
4,37,599
16.96
4,25,723
16.51
4,22,362
15.20
4,26,095
15.20
4,11,193
14.81
3,92,248
17.32
3,84,606
17.65
3,90,749
Company Profile
Overview of Biocon Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.
Biocon Limited is an India-based biopharmaceutical company, engaged in the manufacture of biotechnology products and research services. The Company is in the business of manufacturing active pharmaceutical ingredients (APIs) and formulations, including biosimilar drugs for diabetics, oncology and autoimmune diseases. The Company’s segment includes Generics, Biosimilars, Novel Biologics and Research Services. It focuses on three key therapeutic areas - Oncology, Diabetes, and Immunology. Its APIs portfolio includes cardiovascular, anti-diabetics, immunosuppressants, and specialty molecules. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. Its APIs manufacturing facilities with capabilities in microbial fermentation, downstream process, including chromatographic purification, chemical synthesis, peptide synthesis and Highly Potent APIs (HPAPIs). It has over five facilities in Bangalore, Hyderabad and Visakhapatnam in India.
Biocon Limited is an India-based biopharmaceutical company, engaged in the manufacture of biotechnology products and research services. The Company is in the business of manufacturing active pharmaceutical ingredients (APIs) and formulations, including biosimilar drugs for diabetics, oncology and au...